High pathologic complete remission rate with liposome-encapsulated doxorubicin plus paclitaxel plus trastuzumab as primary treatment in HER-2 positive operable breast cancer: clinical experience

被引：0
|
作者：
Gavila, J. [1 ]
Guerrero-Zotano, A. [1 ]
Climent, M. A. [1 ]
Blanch, S. [1 ]
Guillem, V. [1 ]
Camp, J. [1 ]
Tortajada, M. I. [1 ]
Gozalbo, F. [1 ]
Vidal, P. [1 ]
Ruiz, A. [1 ]
机构：
[1] Fdn Inst Valenciano Oncol, Valencia, Spain
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70066-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：68 / 69
页数：2
相关论文
共 50 条
  • [31] Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial)
    Guarneri, Valentina
    Frassoldati, Antonio
    Piacentini, Federico
    Jovic, Gordana
    Giovannelli, Simona
    Oliva, Cristina
    Conte, PierFranco
    CLINICAL BREAST CANCER, 2008, 8 (02) : 192 - 194
  • [32] Phase II neoadjuvant trial of Interferon-gamma plus weekly paclitaxel, trastuzumab and pertuzumab in patients with HER-2 positive breast cancer
    Han, Hyo S.
    Costa, Ricardo
    Armaghani, Avan
    Soyano, Aixa
    Loftus, Loretta
    Soliman, Hatem
    Fridley, Brooke
    Whiting, Junmin
    Cerezo, Aiana
    Rosa, Marilin
    Extermann, Martine
    Khong, Hung
    Czerniecki, Brian
    CANCER RESEARCH, 2022, 82 (04)
  • [33] Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer
    Ardavanis, Alexandros
    Kountourakis, Panteleimon
    Kyriakou, Flora
    Malliou, Savoula
    Mantzaris, Ioannis
    Garoufali, Anastasia
    Yiotis, Ioulia
    Scorilas, Andreas
    Baziotis, Nikolaos
    Rigatos, Gerasimos
    ONCOLOGIST, 2008, 13 (04): : 361 - 369
  • [34] A multicenter randomized phase III trial of nonpegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide (MC) versus liposome-encapsulated doxorubicin citrate plus vinorelbine (MV) as first-line treatment in locally advanced (LABC) or metastatic breast cancer (MBC)
    Lorusso, V.
    Giotta, F.
    Bordonaro, R.
    Maiello, E.
    Del Prete, S.
    Gebbia, V.
    Filippelli, G.
    Pisconti, S.
    Cinieri, S.
    Romito, S.
    Riccardi, F.
    Cairo, G.
    Chiuri, V. E.
    Ciccarese, M.
    Forcignano, R.
    Petrucelli, L.
    Saracino, V.
    Colucci, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Adding anthracycline plus cyclophosphamide to adjuvant paclitaxel plus trastuzumab might be more reasonable in stage I hormone receptor negative HER-2 positive breast cancer patients
    Altundag, Kadri
    JOURNAL OF BUON, 2018, 23 (05): : 1561 - 1561
  • [36] PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
    Qiyun Shi
    Juncheng Xuhong
    Tao Luo
    Jia Ge
    Feng Liu
    Yang Lan
    Qingqiu Chen
    Peng Tang
    Linjun Fan
    Li Chen
    Yan Liang
    Minghao Wang
    Ying Hu
    Yi Zhang
    Xiuwu Bian
    Xiaowei Qi
    Jun Jiang
    British Journal of Cancer, 2023, 128 : 121 - 129
  • [37] Phase II Trial of Neoadjuvant Pegylated Liposomal Doxorubicin with Paclitaxel and Trastuzumab in Patients with Operable Her2-Positive Breast Cancer
    Hyams, D. M.
    Leichman, G. C.
    Klein, P.
    Rietchsel, P.
    Levine, E. G.
    Gebski, V. J.
    Kelley, M. A.
    CANCER RESEARCH, 2009, 69 (24) : 570S - 570S
  • [38] PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
    Shi, Qiyun
    Xuhong, Juncheng
    Luo, Tao
    Ge, Jia
    Liu, Feng
    Lan, Yang
    Chen, Qingqiu
    Tang, Peng
    Fan, Linjun
    Chen, Li
    Liang, Yan
    Wang, Minghao
    Hu, Ying
    Zhang, Yi
    Bian, Xiuwu
    Qi, Xiaowei
    Jiang, Jun
    BRITISH JOURNAL OF CANCER, 2023, 128 (01) : 121 - 129
  • [39] Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice
    Pernas, Sonia
    Gil-Gil, Miguel
    Ochoa de Olza, Maria
    Guma, Anna
    Climent, Fina
    Petit, Anna
    Jesus Pla, Maria
    Garcia-Tejedor, Amparo
    Lopez-Ojeda, Ana
    Falo, Cati
    Fernandez-Otega, Adela
    Mesia, Carlos
    Javier Perez-Martin, Francisco
    Urruticoechea, Ander
    Ramon Germa, Josep
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (03) : 1161 - 1168
  • [40] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Tonyali, Onder
    Benekli, Mustafa
    Berk, Veli
    Coskun, Ugur
    Ozkan, Metin
    Yildiz, Ramazan
    Ucgul, Emel
    Sevinc, Alper
    Uncu, Dogan
    Demirci, Umut
    Buyukberber, Suleyman
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (06) : 981 - 986
12345